ApoE4-specific Misfolded Intermediate Identified by Molecular Dynamics Simulations

The increased risk of developing Alzheimer’s disease (AD) is associated with the APOE gene, which encodes for three variants of Apolipoprotein E, namely E2, E3, E4, differing only by two amino acids at positions 112 and 158. ApoE4 is known to be the strongest risk factor for AD onset, while ApoE3 and ApoE2 are considered to be the AD-neutral and AD-protective isoforms, respectively. It has been hypothesized that the ApoE isoforms may contribute to the development of AD by modifying the homeostasis of ApoE physiological partners and AD-related proteins in an isoform-specific fashion. Here we find that, despite the high sequence similarity among the three ApoE variants, only ApoE4 exhibits a misfolded intermediate state characterized by isoform-specific domain-domain interactions in molecular dynamics simulations. The existence of an ApoE4-specific intermediate state can contribute to the onset of AD by altering multiple cellular pathways involved in ApoE-dependent lipid transport efficiency or in AD-related protein aggregation and clearance. We present what we believe to be the first structural model of an ApoE4 misfolded intermediate state, which may serve to elucidate the molecular mechanism underlying the role of ApoE4 in AD pathogenesis. The knowledge of the structure for the ApoE4 folding intermediate provides a new platform for the rational design of alternative therapeutic strategies to fight AD.

[1]  S. Yokoyama,et al.  Behavior of human apolipoprotein E in aqueous solutions and at interfaces. , 1985, The Journal of biological chemistry.

[2]  R. Mahley,et al.  Small-molecule structure correctors target abnormal protein structure and function: structure corrector rescue of apolipoprotein E4-associated neuropathology. , 2012, Journal of medicinal chemistry.

[3]  L. Mucke,et al.  Dominant negative effects of apolipoprotein E4 revealed in transgenic models of neurodegenerative disease , 2000, Neuroscience.

[4]  R. Swendsen,et al.  THE weighted histogram analysis method for free‐energy calculations on biomolecules. I. The method , 1992 .

[5]  R. Ryan,et al.  Lipid binding-induced conformational changes in the N-terminal domain of human apolipoprotein E. , 1999, Journal of lipid research.

[6]  R. Mahley,et al.  Apolipoprotein E4 Domain Interaction Occurs in Living Neuronal Cells as Determined by Fluorescence Resonance Energy Transfer* , 2004, Journal of Biological Chemistry.

[7]  Pradeep Kota,et al.  Automated minimization of steric clashes in protein structures , 2011, Proteins.

[8]  KumarShankar,et al.  The weighted histogram analysis method for free-energy calculations on biomolecules. I , 1992 .

[9]  R. Mahley,et al.  Apolipoprotein E: far more than a lipid transport protein. , 2000, Annual review of genomics and human genetics.

[10]  G. Rebeck,et al.  Extracellular Proteolysis of Apolipoprotein E (apoE) by Secreted Serine Neuronal Protease , 2014, PloS one.

[11]  R. Mahley,et al.  Increased tau Phosphorylation in Apolipoprotein E4 Transgenic Mice Is Associated with Activation of Extracellular Signal-regulated Kinase , 2004, Journal of Biological Chemistry.

[12]  K. Weisgraber,et al.  Comparison of the stabilities and unfolding pathways of human apolipoprotein E isoforms by differential scanning calorimetry and circular dichroism. , 2002, Biochimica et biophysica acta.

[13]  F. Ding,et al.  Discrete molecular dynamics , 2012 .

[14]  E. Stratikos,et al.  Biophysical analysis of progressive C-terminal truncations of human apolipoprotein E4: insights into secondary structure and unfolding properties. , 2008, Biochemistry.

[15]  D. Holtzman,et al.  The Binding of Apolipoprotein E to Oligomers and Fibrils of Amyloid-β Alters the Kinetics of Amyloid Aggregation , 2014, Biochemistry.

[16]  D. Epps,et al.  Isoform-specific interactions of human apolipoprotein E to an intermediate conformation of human Alzheimer amyloid-beta peptide. , 2005, Chemistry and physics of lipids.

[17]  K. Garai,et al.  Structural differences between apoE3 and apoE4 may be useful in developing therapeutic agents for Alzheimer’s disease , 2012, Proceedings of the National Academy of Sciences.

[18]  Francesca Fanelli,et al.  Wordom: A User-Friendly Program for the Analysis of Molecular Structures, Trajectories, and Free Energy Surfaces , 2010, J. Comput. Chem..

[19]  Peter M. Kasson,et al.  GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit , 2013, Bioinform..

[20]  Radiya M. Sojitrawala,et al.  A monomeric, biologically active, full-length human apolipoprotein E. , 2007, Biochemistry.

[21]  R. Mahley,et al.  Apolipoprotein E: Structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases , 2014, Neurobiology of Disease.

[22]  Pradeep Kota,et al.  Gaia: automated quality assessment of protein structure models , 2011, Bioinform..

[23]  K. Weisgraber,et al.  Apolipoprotein E structure: insights into function. , 2006, Trends in biochemical sciences.

[24]  D A Agard,et al.  Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E. , 1991, Science.

[25]  H. Stanley,et al.  Discrete molecular dynamics studies of the folding of a protein-like model. , 1998, Folding & design.

[26]  A. Fagan,et al.  Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Carl Frieden,et al.  Concerning the structure of apoE , 2013, Protein science : a publication of the Protein Society.

[28]  Amedeo Caflisch,et al.  Wordom: a program for efficient analysis of molecular dynamics simulations , 2007, Bioinform..

[29]  B. Rupp,et al.  Differences in stability among the human apolipoprotein E isoforms determined by the amino-terminal domain. , 2000, Biochemistry.

[30]  B. Rupp,et al.  Apolipoprotein E4 Forms a Molten Globule , 2002, The Journal of Biological Chemistry.

[31]  G. Kolovou,et al.  Apolipoprotein E Polymorphism and Atherosclerosis , 2003, Angiology.

[32]  H. C. Andersen.  Molecular dynamics simulations at constant pressure and/or temperature , 1980 .

[33]  Feng Ding,et al.  Discrete molecular dynamics: an efficient and versatile simulation method for fine protein characterization. , 2012, The journal of physical chemistry. B.

[34]  Feng Ding,et al.  Modeling backbone flexibility improves protein stability estimation. , 2007, Structure.

[35]  Sean Parkin,et al.  Novel mechanism for defective receptor binding of apolipoprotein E2 in type III hyperlipoproteinemia , 1996, Nature Structural Biology.

[36]  K. Weisgraber.  Apolipoprotein E: structure-function relationships. , 1994, Advances in protein chemistry.

[37]  I. Tesseur,et al.  Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice. , 2000, The American journal of pathology.

[38]  K. Weisgraber,et al.  Human Apolipoprotein E4 Domain Interaction , 1996, The Journal of Biological Chemistry.

[39]  M. Pericak-Vance,et al.  Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[40]  D. Elliott,et al.  Isoform-specific proteolysis of apolipoprotein-E in the brain , 2011, Neurobiology of Aging.

[41]  K. Weisgraber,et al.  Modulation of Apolipoprotein E Structure by Domain Interaction , 2005, Journal of Biological Chemistry.

[42]  R. Mahley,et al.  Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[43]  K. Weisgraber,et al.  Understanding the Association of Apolipoprotein E4 with Alzheimer Disease: Clues from Its Structure* , 2009, Journal of Biological Chemistry.

[44]  Irwin D Kuntz,et al.  Apolipoprotein (apo) E4 enhances amyloid beta peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[45]  R. Mahley,et al.  Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[46]  Jianglei Chen,et al.  Topology of human apolipoprotein E3 uniquely regulates its diverse biological functions , 2011, Proceedings of the National Academy of Sciences.

[47]  A. M. Saunders,et al.  Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease , 1994, Nature Genetics.

[48]  Shuangye Yin,et al.  Eris: an automated estimator of protein stability , 2007, Nature Methods.

[49]  Ken A Dill,et al.  Use of the Weighted Histogram Analysis Method for the Analysis of Simulated and Parallel Tempering Simulations. , 2007, Journal of chemical theory and computation.

[50]  R. Ryan,et al.  Impact of apolipoprotein E on Alzheimer's disease. , 2013, Current Alzheimer research.

[51]  S. Estus,et al.  Soluble apoE/Aβ complex: mechanism and therapeutic target for APOE4-induced AD risk , 2014, Molecular Neurodegeneration.

[52]  K. Weisgraber,et al.  Influence of apoE domain structure and polymorphism on the kinetics of phospholipid vesicle solubilization DOI 10.1194/jlr.M200157-JLR200 , 2002, Journal of Lipid Research.

[53]  R. Mahley,et al.  Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. , 1988, Science.

[54]  R. Mahley,et al.  Human apolipoprotein E: the Alzheimer's disease connection , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[55]  B. Berne,et al.  The free energy landscape for beta hairpin folding in explicit water. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[56]  Matthias Orth,et al.  Expression of Human Apolipoprotein E3 or E4 in the Brains ofApoe−/− Mice: Isoform-Specific Effects on Neurodegeneration , 1999, The Journal of Neuroscience.

[57]  Masahiko Watanabe,et al.  Apo E structure determines VLDL clearance and atherosclerosis risk in mice. , 1999, The Journal of clinical investigation.

[58]  B. Berne,et al.  The free energy landscape for β hairpin folding in explicit water , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[59]  M. Phillips,et al.  Molecular mechanism of apolipoprotein E binding to lipoprotein particles. , 2009, Biochemistry.

[60]  R. Mahley,et al.  Small Molecule Structure Correctors Abolish Detrimental Effects of Apolipoprotein E4 in Cultured Neurons* , 2011, The Journal of Biological Chemistry.

[61]  T. Rohn.  Proteolytic Cleavage of Apolipoprotein E4 as the Keystone for the Heightened Risk Associated with Alzheimer’s Disease , 2013, International journal of molecular sciences.

[62]  M. Gross,et al.  Hydrogen/deuterium exchange and electron-transfer dissociation mass spectrometry determine the interface and dynamics of apolipoprotein E oligomerization. , 2011, Biochemistry.

[63]  M. Karplus,et al.  Effective energy functions for protein structure prediction. , 2000, Current opinion in structural biology.

[64]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[65]  Yuko Okamoto,et al.  Generalized-ensemble algorithms: enhanced sampling techniques for Monte Carlo and molecular dynamics simulations. , 2003, Journal of molecular graphics & modelling.

[66]  Tony Wyss-Coray,et al.  Neuron-Specific Apolipoprotein E4 Proteolysis Is Associated with Increased Tau Phosphorylation in Brains of Transgenic Mice , 2004, The Journal of Neuroscience.

[67]  D. Agard,et al.  Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms. , 1994 .

[68]  Huaxi Xu,et al.  Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy , 2013, Nature Reviews Neurology.